Podcasts about TB

Group Chat News is back with the hottest stories of the week including Dee has a new favorite fitness infulencer, are peptides really safe, everything NFL, China's senior-most general is accused of leaking information about the country's nuclear-weapons program to the U.S., NIke's data base got hacked and over a Tb of information was leaked, The future of AI and ways to invest in it, and Delilah Dallas is opening this week!

Most people think they go into your body and make all new tissue… but in actuality, they are a delivery mechanism of growth factors. I call them the ultimate traffic cop. In this episode, the host converses with Dr. Jesse Morse, a physician specializing in regenerative and anti-aging medicine. They delve into the intricacies of stem cells and their various sources, including bone marrow, fat, and donor tissue.  Dr. Morse highlights the role of exosomes and growth factors in the healing process. The discussion also focuses on the prevention and treatment of Achilles tendon tears, emphasizing the importance of blood supply, proper diagnosis, and innovative therapies. Additionally, they explore the benefits and applications of various peptides, including BPC 157, TB 500, and MotC, for enhancing healing, anti-aging, and overall health. Dr. Morse also addresses the significance of nutrition and detoxification in maintaining optimal health and preventing injuries. Dr. Jesse Morse is a Miami-based, double board-certified physician in Family and Sports Medicine who specializes in regenerative medicine, injury recovery, and longevity. Since shifting from traditional sports medicine in 2020, he has focused on non-surgical approaches to tendon and ligament injuries using therapies like PRP, stem-cell–based treatments, exosomes, and peptides, alongside functional and anti-aging strategies centered on mitochondrial health, immune support, toxin reduction, and personalized recovery—helping everyone from active adults to high-performance athletes restore function and prevent major injuries like Achilles tears while educating widely online. Connect with him on: Instagram: https://www.instagram.com/drjessemorse/ — Sports medicine, regenerative medicine & insights Linktree (aggregated links to socials & resources): https://linktr.ee/DrJesseMorse   Supplements, Compounds & Peptides Collagen (protein / connective tissue support): https://www.ncbi.nlm.nih.gov/books/NBK507922/ Vitamin C (collagen activation / antioxidant): https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ Creatine (muscle & mitochondrial support): https://ods.od.nih.gov/factsheets/Creatine-HealthProfessional/ BPC-157 (peptide – tendon & gut healing): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504390/ TB-500 / Thymosin Beta-4 (peptide – tissue repair): https://pubmed.ncbi.nlm.nih.gov/22674782/ GHK-Cu (copper peptide – skin, joints, stem-cell signaling): https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu MOTS-c (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/25174616/ SS-31 / Elamipretide (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/29515116/ Thymosin Alpha-1 (immune modulation peptide): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367996/ LL-37 (antimicrobial / immune peptide): https://pubmed.ncbi.nlm.nih.gov/15184378/ 5-Amino-1MQ (NNMT inhibitor / fat loss): https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1MQ N-Acetylcysteine (NAC – liver & detox support): https://www.ncbi.nlm.nih.gov/books/NBK537183/ Glutathione (antioxidant / detox): https://ods.od.nih.gov/factsheets/Glutathione-HealthProfessional/ NAD⁺ / NMN / NR (mitochondrial & anti-aging support): NMN: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-mononucleotide NR: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-riboside Regenerative & Injection Therapies PRP – Platelet-Rich Plasma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990861/ Bone Marrow–Derived Stem Cells (BMAC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630382/ Adipose-Derived Stem Cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416130/ Amniotic / Placental Tissue Products: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124018/ Exosomes (cell signaling vesicles): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465611/ Ultrasound-Guided Injections: https://radiopaedia.org/articles/musculoskeletal-ultrasound-guided-injection Needle Tenotomy (scar-tissue disruption): https://pubmed.ncbi.nlm.nih.gov/30428129/ Detox, Blood & Environmental Interventions Sauna (heat detox & cardiovascular benefit): https://www.health.harvard.edu/staying-healthy/saunas-and-your-health Binders – Modified Citrus Pectin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452227/ GI Detox / Toxin Binders (general concept): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654245/ Heavy Metal Chelation (DMPS concept): https://pubmed.ncbi.nlm.nih.gov/12198644/ Mercury Toxicity: https://www.cdc.gov/mercury/index.html Microplastics in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068600/ EBOO Therapy (ozone-based blood filtration): https://pubmed.ncbi.nlm.nih.gov/36681461/ Therapeutic Plasma Exchange (TPE): https://www.ncbi.nlm.nih.gov/books/NBK557561/ INUSpheresis (advanced plasma filtration): https://pubmed.ncbi.nlm.nih.gov/37324197/ Medications & Drug Classes Mentioned Corticosteroids (Prednisone – tendon risk): https://medlineplus.gov/druginfo/meds/a601102.html Fluoroquinolone Antibiotics (tendon rupture risk): https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-fluoroquinolone-antibiotics GLP-1 Agonists (Semaglutide / Tirzepatide / Retatrutide discussion): Semaglutide: https://pubmed.ncbi.nlm.nih.gov/36421543/ Tirzepatide: https://pubmed.ncbi.nlm.nih.gov/35220624/ Nutrition & Food-Related Mentions Protein Intake & Muscle Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566799/ American Gluten vs European Wheat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799814/ Seed Oils & Inflammation (discussion topic): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196963/ Dairy & Inflammation (contextual mention): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122229/ Key Mechanisms & Concepts Poor Blood Supply in Achilles Tendon (Watershed Zone): https://pubmed.ncbi.nlm.nih.gov/17021202/ Mitochondrial Dysfunction & Aging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843959/ Stem Cells as "Medicinal Signaling Cells": https://pubmed.ncbi.nlm.nih.gov/25784997/   Show Notes 00:00 Introduction to Exosomes and Stem Cells 01:01 Dr. Morse's Background and Transition to Regenerative Medicine 02:03 Achilles Tendon Tears: Causes and Prevention 05:02 Preventative Measures and Treatments for Achilles Injuries 10:26 The Role of Nutrition in Tendon Health 12:53 Peptides and Their Impact on Tendon Health 15:50 Stem Cells: Misconceptions and Applications 20:52 Comparing Stem Cell Sources and Their Potency 29:52 The Controversy of International Stem Cell Treatments 34:04 Cleaning Toxins from Your Blood 34:19 The Toxic Burden in Our Environment 35:57 Practical Detox Methods 37:47 Mercury and Heavy Metal Testing 44:47 The Problem with American Gluten 46:49 Underrated Peptides for Health 53:42 Growth Hormone and Anti-Aging 01:03:34 Advanced Blood Cleaning Techniques 01:04:51 Conclusion and Contact Information   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

01-20-26 Tyler Toffoli Goal SJ 1 TB 0 by San Jose Sharks

01-20-26 Brandon Hagel-TB-Goal SJ 1 TB 1 by San Jose Sharks

Game 49: SJ 1 at TB 4 FINAL. TT: 00:09:34

„Vnimanie! Vnimanie!“ Takto sa obyvatelia mesta Pripjať 27. apríla 1986 dozvedali z megafónov a sirén - po prvý raz oficiálne a takmer po dvoch dlhých dňoch – o katastrofe, ktorá sa odohrala v neďalekej jadrovej elektrárni Černobyľ. Z tejto, dnes už legendárnej, seriálovej scény automaticky prechádza mráz po chrbte. Situácia, keď sami cítite, že sa deje niečo veľmi zlé, ale všetci kompetentní zaryto mlčia, je presne tým obrazom, v ktorom sme žili aj my – občania komunistického Československa. Mnohí si dodnes na to pamätajú – na informačné embargo, na to ako sa zvesti o približujúcej sa hrozbe šírili len zlovestnou šepkandou i na prvomájové sprievody, do ktorých sa pod holým nebom – zamorovaného z východu rádioaktívnym mrakom - museli zapojiť všetci. Oslavoval sa komunistický sviatok práce a vo vzduchu nad hlavami viselo nebezpečenstvo, o rozsahu ktorého ľudia netušili. V tomto roku si budeme aj v našom mesačníku Historická revue pripomínať 40. výročie černobyľskej jadrovej katastrofy. Tá sa neodohrávala len v Sovietskom zväze, neďaleko ukrajinského Kyjeva. Vo väčšej či menšej miere zasahovala do celej Európy, mala bezpochyby globálny dopad. Čo to však bolo za prekvapenie, keď sa o skutočnej hrozbe i ľudia na Slovensku dozvedali len zo západného rozhlasu či v listoch od svojich známych žijúcich na kapitalistickom Západe? Čo sa to deje, keď rakúski a západonemeckí pohraničníci otáčajú celé vlakové súpravy späť do Československa? A prečo ľudia prestávajú v obchodoch nakupovať mlieko, ovocie či zeleninu? Prečo vláda a strana mlčia, čo nám zatajujú? Tento raz sa v podcaste Dejiny pozrieme na to, ako sa i u nás na Slovensku zatĺkalo, ako sa zatajoval a úmyselne zľahčoval rozsah černobyľskej katastrofy. Ale i o tom, ako informovanosť a nálady verejnosti monitorovala ŠtB. Rozprávať sa budem s historikom Petrom Jašekom z Ústavu pamäti národa. – Ak máte pre nás spätnú väzbu, odkaz alebo nápad, napíšte nám na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠jaroslav.valent@petitpress.sk⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Všetky podcasty denníka SME nájdete na ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠sme.sk/podcasty⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠See omnystudio.com/listener for privacy information.

Join My Private Group: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://theaxioncollective.manus.space/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email List: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://huntershealthhacks.beehiiv.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get My Book On Amazon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://a.co/d/avbaV48Download⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Peptide Cheat Sheet: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://peptidecheatsheet.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Download The Bioregulator Cheat Sheet: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bioregulatorcheatsheet.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1 On 1 Coaching Application: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamscoaching.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Book A Call With Me: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamscall.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Supplement Sources: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamssupplements.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Storefront: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Socials:Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/hunterwilliamscoaching/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Video Topic Request: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamsvideotopic.carrd.co/⁠⁠⁠In today's episode, I tackle one of the most confusing and emotionally charged topics I've seen circulate in the peptide space recently: the claim that Glow and CLO peptide blends are unstable, ineffective, or “dead on arrival.”This isn't a response video and it's not a debate for clicks. It's a systematic, education-first breakdown of the actual arguments being made, where those arguments come from, and whether they hold up under real scientific scrutiny.I walk you through:The steel-man case against blending peptides like GHK-Cu, BPC-157, TB-500, and KPVWhy certain claims sound scientific but fall apart when you check amino acid sequences, chemistry, and real stability dataHow AI-hallucinated or misattributed studies are increasingly being used to scare people in the peptide worldWhat real peptide stability science actually tells us about pH, copper coordination, aggregation, oxidation, and storageAnd why independent HPLC and degradation testing from multiple labs matters more than viral talking pointsI also share real-world context: how fear-based content drives engagement on social media, why I intentionally don't operate that way, and why education, transparency, and trust matter more to me than shock value or “gotcha” arguments.At the end of the day, my position is simple:I don't claim absolute truth. I do believe in doing the work, checking sources, looking at data, and helping people make informed decisions without fear.If you've been wondering whether Glow or CLO blends are a waste of money — or if you've felt confused by the conflicting information online — this episode is meant to bring clarity, not controversy.As always, I encourage you to verify everything for yourself, seek out opposing views, and decide what makes sense for you.

James catches up with his old friend, big pharma industry exec turned poacher Sasha Latypova. On the menu: rabies isn't real; cows don't ‘catch' TB; our governments are deliberately trying to kill us with vaccines, as Sasha is hoping to testify in a landmark court case in the Netherlands. https://sashalatypova.substack.com ↓ ↓ ↓ If you need silver and gold bullion - and who wouldn't in these dark times? - then the place to go is The Pure Gold Company. Either they can deliver worldwide to your door - or store it for you in vaults in London and Zurich. You even use it for your pension. Cash out of gold whenever you like: liquidate within 24 hours. https://bit.ly/James-Delingpole-Gold ↓ ↓ How environmentalists are killing the planet, destroying the economy and stealing your children's future. In Watermelons, an updated edition of his ground-breaking 2011 book, JD tells the shocking true story of how a handful of political activists, green campaigners, voodoo scientists and psychopathic billionaires teamed up to invent a fake crisis called ‘global warming'. This updated edition includes two new chapters which, like a geo-engineered flood, pour cold water on some of the original's sunny optimism and provide new insights into the diabolical nature of the climate alarmists' sinister master plan. Purchase Watermelons by James Delingpole here: https://jamesdelingpole.co.uk/Shop/ ↓ ↓ ↓ Buy James a Coffee at: https://www.buymeacoffee.com/jamesdelingpole The official website of James Delingpole: https://jamesdelingpole.co.uk x

Join My Private Group: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://theaxioncollective.manus.space/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email List: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://huntershealthhacks.beehiiv.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get My Book On Amazon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://a.co/d/avbaV48Download⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠The Peptide Cheat Sheet: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://peptidecheatsheet.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Download The Bioregulator Cheat Sheet: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bioregulatorcheatsheet.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠1 On 1 Coaching Application: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamscoaching.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Book A Call With Me: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamscall.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Supplement Sources: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamssupplements.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Storefront: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Socials:Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/hunterwilliamscoaching/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Video Topic Request: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamsvideotopic.carrd.co/⁠⁠⁠In today's episode, I'm doing a much-needed update on one of the most underrated peptides in the entire space: VIP (Vasoactive Intestinal Peptide). This is one of those “ancillary” peptides that people usually only associate with lungs or mold, but the deeper you go, the more you realize VIP is a master regulator that touches almost every major system in the body.I walk you through what VIP actually is (a 28–amino acid peptide discovered in 1970), why it's produced all over the body (brain, lungs, heart, gut, endocrine organs), and why it works so differently than peptides like BPC-157, TB-500, or the GLP-1s. We'll cover the core mechanisms in a way that's technical but practical: VPAC1/VPAC2 receptors, cAMP signaling, smooth muscle relaxation, glandular secretion, and immune modulation.Then I zoom out into a broad “survey” of VIP's real-world use cases: lung function and oxygenation, gut motility and stool quality, autoimmune regulation, brain fog, mood/anxiety, circadian rhythm, and even dysautonomia patterns like POTS and long COVID. I also break down dosing best practices for subcutaneous vs intranasal, what to expect the first time you use it (including the niacin-like flush), and how I personally think about cycling VIP long-term.

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and vice chair of academic affairs here at the City of Hope Comprehensive Cancer Center, Los Angeles. Today, I'm thrilled to be joined by Dr. Hope Rugo, an internationally renowned breast medical oncologist and my colleague here at City of Hope, where she leads the Women's Cancers Program and serves as division chief of breast medical oncology. Dr. Rugo is going to share with us exciting advances in antibody-drug conjugates (ADCs) that are expanding treatment options in various breast cancer types. She'll also address some of the complex questions arising in the new era of oral SERDs (selective estrogen receptor degraders) that are revolutionizing treatment in the hormone receptor-positive breast cancer space. Our full disclosures are available in the transcript of this episode.  Dr. Rugo, welcome, and thanks so much for being on the podcast today. Dr. Hope Rugo: Thank you. Pleasure to be here. Dr. Monty Pal: So, I'm going to switch to first names if you don't mind.  The first topic is actually a really exciting one, Hope, and this is antibody-drug conjugates. I don't know if I've ever shared this with you, but I actually started my training at UCLA, I was a med student and resident there, and it was in Dennis Slamon's lab. I worked very closely with Mark Pegram and a handful of others. This is right around the time I think a lot of HER2-directed therapies were really evolving initially in the clinics. Now we've got antibody-drug conjugates. Our audience is well-familiar with the mechanism there but tell us about how ADCs have really started to reshape therapy for HER2-positive breast cancer. Dr. Hope Rugo: Yeah, I mean, this is a really great place to start. I mean, we have had such major advances in breast cancer just this year, I think really changing the paradigm of treating patients. But HER2-positive disease, we've been used to having sequenced success of new agents. And I think the two biggest areas where we've made advances in HER2-positive disease, which were remarkably advanced this year in 2025, have been in antibody-drug conjugates with trastuzumab deruxtecan and with new oral tyrosine kinase inhibitors (TKIs) that have less of a target on EGFR and more on HER2, so they have an overall more tolerable toxicity profile and therefore a potentially better efficacy in the clinic. At least that's what we're seeing with these new strategies that we couldn't really pursue in the past because of toxicities of the oral TKIs. So, although our topic is ADCs, I'm going to include the TKI because it's so important in our thinking about treating HER2-positive disease. In the metastatic setting, we've seen these remarkable improvements in progression-free and overall survival in the second-line setting with T-DXd, or trastuzumab deruxtecan, compared to T-DM1. And then sequencing ADCs with giving T-DXd after T-DM1 was better than an oral tyrosine kinase or a trastuzumab combination with standard chemotherapy. That was DESTINY-Breast03 and DESTINY-Breast02. So, then we've had other trials since then, and T-DXd has moved into the early-stage setting, which I'll talk about in just a moment. But the next big trial for T-DXd in HER2-positive disease was moving it to the first-line setting to supplant what has become an established treatment for now quite a long time: the so-called CLEOPATRA regimen, which used the combined antibodies trastuzumab, pertuzumab with a taxane as first-line therapy. And then we've proceeded on with maintenance with ongoing HP for patients with responding or stable disease. And we'd seen long-term data showing, you know, at 8 years there was a group of patients whose cancers had never progressed and continued improved overall survival. So, T-DXd was studied in DESTINY-Breast09, either alone or in combination with pertuzumab compared to THP. The patient population had received a little bit more prior treatment, but interestingly, not a lot compared to CLEOPATRA. And they designed the trial to be T-DXd continued until progression with or without pertuzumab versus THP, which would go for six cycles and then stop around six cycles, and then stop and continue HP. Patients who had hormone receptor-positive disease could use hormone therapy, and this is one of the issues with this dataset because, surprisingly in this dataset and one other I'll mention, very few patients took hormone therapy. And even in the maintenance trial, the HER2CLIMB-05, less than 50% took hormone therapy as maintenance. This is kind of shocking to me and highlights an area of really important education, that outcome is improved when you add endocrine therapy for hormone receptor-positive HER2-positive metastatic disease in the maintenance phase, and it's a really important part of treatment. But suffice it to say, you know, you're kind of studying continued chemo versus stopping chemo in maintenance. And T-DXd, as we all expected, in combination with pertuzumab was superior to THP in terms of progression-free survival, really remarkably improved. And you could stop the chemo with toxicity, but most people continued it with T-DXd. Again, not a lot of people got hormone therapy, which is an issue, and you stop the chemo in the control arm. So, this has brought up a lot of interest in trying to use T-DXd as an induction and then go to maintenance, much as we do with the CLEOPATRA regimen with hormone therapy. But it brings up another issue. So first, T-DXd is superior; it's a great treatment. Not everybody needs to have it because we don't know whether it's better to give T-DXd first or second with progression - that we need a little bit longer follow-up. But just earlier this week, interestingly, the third week of December, the U.S. FDA approved T-DXd in the DESTINY-Breast09 approach with pertuzumab. So as I mentioned earlier, there was a T-DXd-alone arm; that arm has not yet reported. So very interesting, we don't know if you need pertuzumab or not. So what about the maintenance? That's the other area where we've made a huge advance here. So, we all want to stop chemo and we want to stop T-DXd. You don't want somebody being nauseated for two years while they're on treatment, and also there's a small number of patients with mostly de novo metastatic HER2-positive disease who are cured of their disease. We'd like to expand that, and I think these new drugs give us the opportunity to improve the number of patients who might be cured from metastatic disease. So the first maintenance study we saw was adding palbociclib, the CDK4/6 inhibitor, to endocrine therapy and HP, essentially. There, we had a remarkable improvement in progression-free survival difference of 15.2 months: 29 to 44 months, really huge. At San Antonio this year, we saw data with this oral tyrosine kinase inhibitor tucatinib, already showed it was great in a triplet, but as maintenance in combination with HP, it showed also a remarkable improvement in progression-free survival. But the numbers were all shifted down. So in PATINA, the control arm was in the 24-month range; here it was the tucatinib-HP arm that was in the 25 months and 16 months for control. So there was a differential benefit in ER-negative and ER-positive disease. So I think we're all thinking that our ideal approach moving forward would be to give T-DXd to most patients, we see how they do, and treat to best response. And then, stop the T-DXd, start HP, trastuzumab, pertuzumab for ER-negative, with tucatinib for ER-positive with palbociclib. We also have early data that suggests that both approaches may reduce the development of brain metastases, an issue in HER2-positive disease, and delay time to progression of brain metastases as seen in HER2CLIMB-05 in very early data - small numbers, but still quite intriguing that you might delay progression of brain metastases with tucatinib that clearly has efficacy in the brain.  So, I think that this is a hugely exciting advance for our patients, and these approaches are quickly moving into the early stage setting. T-DXd compared to standard chemo, essentially followed by THP, so a sequenced approach resulted in more pathologic complete responses than a standard THP-AC-type neoadjuvant therapy. T-DXd alone for eight cycles wasn't better, and that's interesting. We still need the sequenced non-cross-resistant chemo. But I think even more importantly, the data from DESTINY-Breast05 looking at T-DXd versus T-DM1 in patients with residual disease after neoadjuvant HER2-targeted therapy showed a remarkable improvement in invasive disease-free survival with T-DXd versus T-DM1, and quite early. It was a high-risk population, higher risk than the T-DM1 trial with KATHERINE, but earlier readout with a remarkable improvement in outcome. We expect to be FDA approved sometime in the first half of 2026. So then we'll get patients who've already had T-DXd who get metastatic disease. But my hope is that with T-DXd, maybe with tucatinib in the right group of patients or even sequenced in very high-risk disease, that we could cure many more patients with early-stage HER2-positive breast cancer and cure a subset, a greater subset of patients with de novo metastatic disease. Dr. Monty Pal: That's brilliant. And you tackled so many questions that I was going to follow up with there: brain metastases, etc. That was sort of looming in my mind. I mean, general thoughts on an ADC versus a TKI in the context of brain mets? Dr. Hope Rugo: Yeah, it's an interesting question because T-DXd has shown quite good efficacy in this setting. And tucatinib, of course, had a trial where they took patients with new brain mets, so a larger population than we've seen yet for the T-DXd trials, and saw that not only did they delay progression of brain metastases and result in shrinkage of existing untreated brain mets, but that patients who develop a new brain met, they could stay on the same assigned treatment. They got stereotactic radiation, and then the patients who were on tucatinib with trastuzumab and capecitabine had a further delay in progression of brain mets compared to those on the placebo arm, even after treatment of a new one that developed on treatment. So, I think it's hard. I think most of us for a lot of brain mets might start with the tucatinib approach, but T-DXd is also a very important treatment. You know, you're kind of trading off a diarrhea, some liver enzyme elevations with tucatinib versus nausea, which you really have to work on managing because it can be long-delayed nausea, and this risk of ILD, interstitial lung disease, that's about 12%, with most but not all trials showing a mortality rate from interstitial lung disease of just under 1 percent. In the early-stage setting, it was really interesting to see that with T-DXd getting four cycles in the neoadjuvant setting, a lot less ILD noted than the patients who got up to 14 cycles, as I think they got a median of 10 cycles in the post-surgical setting, there was a little bit more ILD. But I think we're going to be better and better at finding this earlier and preventing mortality by just stopping drug and treating earlier with steroids. Dr. Monty Pal: And this ILD issue, it always seems to resurface. There are drugs that I use in my kidney cancer clinic, everolimus, common to perhaps the breast cancer clinic as well, pembrolizumab, where I think the pattern of pneumonitis is quite different, right? What is your strategy for recognizing pneumonitis early in this context? Dr. Hope Rugo: Well, it is, and you know, having done the very early studies in everolimus where we gave it in the neoadjuvant setting and we're like, "Hmm, the patient came in with a cough. What's going on?" You know, we didn't know. And you have mouth sores, you know, we were learning about the drug as we were giving it. What we don't do with everolimus and CDK4/6 inhibitors, for example, is grade 1 changes like radiation pneumonitis, we don't stop, we don't treat it. We only treat for symptoms. But because of the mortality associated with T-DXd, albeit small, we stop drug for grade 1 imaging-only asymptomatic pneumonitis, and some of us treat with a half dose of steroids just to try and hasten recovery. We've actually now published or presented a couple of datasets from trials, a pooled analysis and a real-world analysis, that have looked at patients who were retreated after grade 1 pneumonitis or ILD and tolerated drug very well and none of them died of interstitial lung disease, which was really great to see because you can retreat safely and some of these patients stayed on for almost a year benefiting from treatment. So, there's a differential toxicity profile with these drugs and there are risk factors which clearly have identified those at higher risk: prior ILD, for example. A French group said smoking; other people haven't found that, maybe because they smoked more in France, I don't know. And being of Japanese descent is quite interesting. The studies just captured that you were treated in Japan, but I think it's probably being of Japanese descent with many drugs that increases your risk of ILD. And, you know, older patients, people who have hypoxia, those are the patients. So, how do we do this? With everolimus, we don't have specific monitoring. But for T-DXd we do; we do every nine weeks to start with and then every 12 weeks CT scans because most of the events occur relatively early. Somebody who's older and at higher risk now get the first CT at six weeks. Dr. Monty Pal: This is super helpful. And I have to tell you, a lot of these drugs are permeating the bladder cancer space which, you know, is ultimately going to be a component of my practice, so thank you for all this. We could probably stay on this topic of HER2-positive disease forever. I'm super interested in that space still. But let me shift gears a little bit and talk about triple-negative breast cancer and this evolving space of HR-positive, HER2-low breast cancer. I mean, tell us about ADCs in that very sort of other broad area. Dr. Hope Rugo: So triple-negative disease is the absolute hardest subset of disease that we have to treat because if you don't have a great response in the early stage setting, the median survival is very short, you know, under two years for the majority of TNBCs, with the exception of the small percentage of low proliferative disease subsets. The co-question is what do we do for these patients and how do we improve outcome? And sacituzumab govitecan has been one strategy in the later line setting that was shown to improve progression-free and overall survival, the Trop-2 ADC. We had recently three trials presented with the two ADCs, sacituzumab govitecan and the other Trop-2 ADC that's approved for HR-positive disease, datopotamab deruxtecan. And they were studied in the first-line setting. Two trials with SG, sacituzumab govitecan, those trials, one was PD-L1 positive, ASCENT-04. That showed that SG with a checkpoint inhibitor was superior, so pembrolizumab was superior to the standard KEYNOTE-355 type of treatment with either a taxane or gemcitabine and carboplatin with pembrolizumab for patients who have a combined positive score for PD-L1, 10 or greater. So, these are patients who are eligible for a checkpoint inhibitor, and SG resulted in an improved progression-free survival.  The interesting thing about that dataset is that few patients had received adjuvant or neoadjuvant checkpoint inhibitor, which is fascinating because we give it to everybody now. But access is an issue and timing of the study enrollment was an issue. The other thing which I think we've all really applauded Gilead for is that there was automatic crossover. So, you could get from the company, to try and overcome some of the enormous disparities worldwide in access to these life-saving drugs, you could get SG through the company for free once you had blinded independent central review confirmation of disease progression. Now, a lot of the people who got the SG got it through their insurance, they didn't bill the company, but 80 percent of patients in the control arm received SG in the second-line setting. So that impacts your ability to look at overall survival, but it's an incredibly important component of these trials. So then at ESMO, we saw the data from SG and Dato-DXd in the first-line metastatic setting for patients who either had PD-L1-negative disease or weren't eligible for an immunotherapy. For the Dato study, TROPION-Breast02, that was 10 percent of the patients who had PD-L1-positive disease but didn't get a checkpoint inhibitor, and for the ASCENT-03 trial population it was only 1 percent. Importantly, the trials allowed patients who relapsed within a year of receiving their treatment with curative intent, and the Dato study, TB-02, allowed patients who relapsed while on treatment or within the first six months, and that was 15 percent of the 20 percent of early relapsers. The ASCENT trial, ASCENT-03, had 20 percent who relapsed between 6 and 12 months. The drugs were better than standard of care chemotherapy, the ADCs in both trials, which is very nice. Different toxicity profiles, different dosing intervals, but better than standard of care chemotherapy in the disease that's hardest for us to treat. And importantly, when you looked at the subset of early relapsers, those patients also did better with the ADC versus chemotherapy, which is incredibly important. And we were really interested in that 15 percent of patients who had early relapse. I actually think that six months thing was totally contrived, invented, you know, categorization and doesn't make any sense, and we should drop it. But the early relapsers were 15 percent of TB-02 and Dato was superior to standard of care chemo. We like survival, but the ASCENT trial again allowed the crossover to an approved ADC that improved survival and 80 percent of patients crossed over. In the Dato trial, they did not allow crossover, they didn't provide Dato, which isn't approved for TNBC but is for HR-positive disease, and they didn't allow, of course, pay for SG. So very few patients actually crossed over in their post-treatment data and in that study, they were able to show a survival benefit. So actually, I think in the U.S. where we can use approved drugs already before there's a fixed FDA approval, that people are already switching to use SG or Dato in the first-line setting for metastatic TNBC that's both PD-L1 positive for SG and PD-L1 negative for both drugs. And I think understanding the toxicity profiles of the two drugs is really important as well as the dosing interval to try and figure out which drug to use. Dr. Monty Pal: Brilliant. Brilliant. Well, I'm going to shift gears a little bit. ADCs are a topic, again, just like HER2-positive disease we could stay on forever. Dr. Hope Rugo: Huge. Yes. Dr. Monty Pal: But we're going to shift gears to another massive topic, which is oral SERDs. In broad strokes, right, this utilization of CDK4/6 inhibitors in the context of HR-positive breast cancer is obviously, you know, a paradigm that's been well established at this point. Where do we sequence in oral SERDs? Where do they fit into this paradigm? Dr. Hope Rugo: Ha! This is a rapidly changing area; we keep changing what we're saying every other minute. And I think that there are three areas of great interest. So one is patients who develop ESR1 mutations that allow constitutive signaling through the estrogen receptor, even when there's not estrogen around, and that is a really important mutation that is subclonal; it develops under the pressure of treatment in about 40 percent of patients. And it doesn't happen when you first walk in the door. And what we've seen is that oral SERDs as single agents are better than standard single-agent endocrine therapy in that setting. The problem that we've had with that approach is that we're now really interested in giving targeted agents with our endocrine therapies, not just in the first-line setting where CDK4/6 inhibitors are our standard of care with survival benefit for ribociclib and, you know, survival benefit in subsets with other CDK4/6 inhibitors, and abemaciclib with a numeric improvement. So we give it first line. The question is, what do you do in the second-line setting? Because of the recent data, we now believe that oral SERDs should be really given with a targeted agent. And some datasets which were recently presented, which I think have helped us with that, have been EMBER-3 and then the most recently evERA BC, or evERA Breast Cancer, that looked at the oral SERD giredestrant with everolimus compared to standard of care endocrine therapy with everolimus, where 100 percent of patients received prior CDK4/6 inhibitor and showed a marked improvement in progression-free survival, including in the subsets of patients with a short response, 6-12 months of prior response to CDK4/6 inhibitor and in those who had a PIK3CA pathway mutation. The thing is that the benefit looks like it's much bigger in the ESR1 mutant population, although response was better, PFS wasn't better in the wild type. So, we're still trying to figure that out. We also saw EMBER-3 with imlunestrant and abemaciclib as a second line. Not everybody had had a prior CDK4/6 inhibitor; they compared it to imlunestrant alone, but still the data was quite striking and seemed to cross the need for ESR1 mutations. And then lastly, we saw data from the single arms of the ELEVATE trial looking at elacestrant with everolimus and abemaciclib and showed these really marked progression-free survival data, even though single-arm, that crossed the mutation status. At least for the everolimus combination, abemaciclib analysis is still to come in the mutated subgroups. But really remarkable PFS, much longer.  Single-agent fulvestrant after CDK4/6 inhibitor AI has a PFS in like the three-month range and in some studies, maybe close to five months. These are all at 10-plus months and really looking very good. And so those questions are, is it ESR1 mutation alone? Is it all comers? We'd like all comers, right? We believe in the combination approach and we're learning more about combinations with drugs like capivasertib and other drugs as we move forward. Everybody now wants to combine their targeted agent with an oral SERD because they're clearly here to stay with quite remarkable data. The other issue, so the second issue in the metastatic setting is, does it make a difference if we change to an oral SERD before radiographic imaging evidence of progression? And that was the question asked in the SERENA-6 trial where patients had serial monitoring for the presence of ESR1 mutations in ctDNA. And those who had them without progression on imaging could be randomized to switch to camizestrant with the same CDK4/6 inhibitor or stay on their same AI CDK4/6 inhibitor. And they showed a difference in progression-free survival that markedly favored camizestrant. But interestingly, the people who were on the standard control arm had an ESR1 mutation, we think AIs don't work, they stayed on for nine more months. The patients who were on the camizestrant stayed on for more than 16 months. And they presented some additional subset data which showed the same thing: follow-up PFS data, PFS2, all beneficial in SERENA-6 at the San Antonio [Breast Cancer Symposium]. So, we're still a little bit unclear about that. They did quality of life, and pain was markedly improved. They had a marked delayed time to progression of pain in the camizestrant arm. So this is all a work in progress, trying to understand who should we switch without progression to an oral SERD based on this development of this mutation that correlates with resistance. And, you know, it's interesting because the median time to having a mutation was 18 months and the median time to switch was almost 24 months. And then there were like more than 3,000 patients who hadn't gotten a mutation, hadn't switched, and were still okay. So screening everybody is the big question, and when you would start and who you would change on and how this affects outcome. Patients didn't have access to camizestrant in the control arm, something we can't fix but we have experimental drugs. We're actually planning a trial, I hope in collaboration with the French group Unicancer, and looking at this exact question. You know, if you switch and you change the CDK4/6 inhibitor and then you also allow crossover, what will we see? Dr. Monty Pal: We're coming right to the tail end of our time here, and I could probably go on for another couple of hours with you here. But if you could just give us maybe one or two big highlights from San Antonio, any thoughts to leave our audience with here based on this recent meeting? Dr. Hope Rugo: Yeah, I mean, I talked about a lot of those new data already from San Antonio, and the one that I'd really like to mention which I think was, you know, there were a lot of great presentations including personalized screening presented from the WISDOM trial by my colleague Laura Esserman, fascinating and really a big advance. But lidERA was the big highlight, I think, outside of the HER2CLIMB-05 which I talked about earlier in HER2-positive disease. And this study looked at giredestrant, the oral SERD versus standard of care endocrine therapy as treatment for medium and high-risk early-stage breast cancer. And what they showed, which I think was really remarkable with just about a three-year median follow-up, was an improvement in invasive disease-free survival with a hazard ratio of 0.7. I mean, really quite remarkable and so early. It looked as though this was all driven by the high-risk group, which makes sense, not the medium risk, it's too early. And also that there was a bigger benefit in patients who were on tamoxifen compared to giredestrant versus AI, but for both groups, the confidence intervals didn't cross 1. There's even a trend towards overall survival, even though it's way too early. I think that, you know, really well-tolerated oral drug that could improve outcome in early-stage disease, this is the first advance we've seen in over two decades in the treatment of early-stage hormone receptor-positive disease with just endocrine therapy. I think we think that we don't want to give up CDK4/6 inhibitors because we saw a survival benefit with abemaciclib and a trend with giving ribociclib in the NATALEE trial. So we're thinking that maybe one approach would be to give CDK4/6 inhibitors and then switch to an oral SERD or to have enough data to be able to give oral SERDs with these CDK4/6 inhibitors for early-stage disease. And that's all in the works, you know, lots of studies going on. We're going to see a lot of data with both switching 8,000 patients with an imlunestrant switching trial, an elacestrant trial going on, and safety data with giredestrant with abemaciclib and soon to come ribociclib. So, this is going to change everything for the treatment of early-stage breast cancer, and I hope cure more patients of the most common subset of the most common cancer diagnosed in women worldwide. Dr. Monty Pal: Super exciting. It's just remarkable to hear how this has evolved since 25 years ago, which is really the last time I sort of dabbled in breast cancer.  Thank you so much, Hope, for joining us today. These were fantastic insights. Appreciate you being on the ASCO Daily News Podcast and really want to thank you personally for your remarkable contribution to the field of breast cancer. Dr. Hope Rugo: Thank you very much, and thanks for talking with me today. Dr. Monty Pal: You got it. And thanks a lot to our listeners today as well. You'll find links to all the studies we discussed today in the transcript of this episode. Finally, if you value the insights that you hear today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinion of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:   Dr. Monty Pal @montypal Dr. Hope Rugo   @hoperugo Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx  

This week we dig into how a dead hard drive took Frigate out, answer your questions, and start a new challenge for the new year. -- During The Show -- 00:50 Intro Sticky Things and Bug reports Electric Dirt Bike Validating work Picking and offering boats Hosting in home lab 10:00 Frigate Frigate drive failure 4 TB drive died Frigate setup Swapping drives and power on hours Running drives into the ground Replacing drives Motion detection 20:06 News Wire Shotcut 25.12 - shotcut.org (https://shotcut.org/blog/new-release-25.12.30/) Ncurses 6.6 - phoronix.com (https://www.phoronix.com/news/Ncurses-6.6) OpenTTD 15.0 - openttd.org (https://www.openttd.org/news/2026/01/01/openttd-15-0) QPrompt 2.0 - patreon.com (https://www.patreon.com/posts/qprompt-2-0-147192236) Mkvtoolnix 97 - mkvtoolnix.download (https://mkvtoolnix.download/windows/releases/97.0/) Privoxy 4.1 - sourceforge.net (https://sourceforge.net/projects/ijbswa/files/Sources/4.1.0%20%28stable%29/) OpenBGPD 9.0 - bsdsec.net (https://bsdsec.net/articles/openbgpd-9-0-released) IceWM - debugpoint.com (https://www.debugpoint.com/icewm-4-0-0-features/) Devuan 6.1 - phoronix.com (https://www.phoronix.com/news/Devuan-6.1-Released) Manjaro 26.0 - manjaro.org (https://forum.manjaro.org/t/manjaro-26-0-anh-linh-released/184526) Qwen Text to Image - venturebeat.com (https://venturebeat.com/technology/open-source-qwen-image-2512-launches-to-compete-with-googles-nano-banana-pro) 27:07 Flatpak vs Packaged Software - Pete New contest! Steve uses packaged software Idea behind flatpaks Flatpak edge cases Install via AUR AppImages 37:16 Backup GrapheneOS - Domink Toilet backup strategy Plan to come back from scratch Contacts VCF file ADB Backup Guide (https://droidwin.com/how-to-create-and-restore-app-backup-via-adb-commands/) ADB Backup Caveat (https://developer.android.com/about/versions/12/behavior-changes-12#adb-backup-restrictions) 45:09 KVM Switch? - Jeremy Now use remote software Barrier (https://github.com/debauchee/barrier) Synergy (https://en.wikipedia.org/wiki/Synergy_%28software%29) Deskflow (https://github.com/deskflow/deskflow) IO Gear KVM (https://iogear.com/collections/cable-kvms-desktop-kvms) Rust Desk (https://rustdesk.com/) -- The Extra Credit Section -- For links to the articles and material referenced in this week's episode check out this week's page from our podcast dashboard! This Episode's Podcast Dashboard (http://podcast.asknoahshow.com/474) Phone Systems for Ask Noah provided by Voxtelesys (http://www.voxtelesys.com/asknoah) Join us in our dedicated chatroom #GeekLab:linuxdelta.com on Matrix (https://element.linuxdelta.com/#/room/#geeklab:linuxdelta.com) -- Stay In Touch -- Find all the resources for this show on the Ask Noah Dashboard Ask Noah Dashboard (http://www.asknoahshow.com) Need more help than a radio show can offer? Altispeed provides commercial IT services and they're excited to offer you a great deal for listening to the Ask Noah Show. Call today and ask about the discount for listeners of the Ask Noah Show! Altispeed Technologies (http://www.altispeed.com/) Contact Noah live [at] asknoahshow.com -- Twitter -- Noah - Kernellinux (https://twitter.com/kernellinux) Ask Noah Show (https://twitter.com/asknoahshow) Altispeed Technologies (https://twitter.com/altispeed)

According to the Guinness Book of World Records, TB is humanity's oldest contagious disease. It has become something of an afterthought in rich nations, but remains the world's most deadly infectious disease. In 2024 it killed more than 1.2 million people.South Africa has one of the highest TB burdens in the world, but it has also developed one of the most sophisticated scientific ecosystems for the study of the disease. Clinical trials conducted in the country have been crucial to the innovation of TB treatments, vaccines, diagnostics and prevention strategies.Much of the funding for this research comes from American institutions. But since early 2025, streams of that money have been withdrawn due to a series of decisions by the Trump administration.Sandra Kanthal visits Cape Town and discovers the story of two intertwined landscapes: the people in local communities struggling with the burden of tuberculosis, and the scientific institutions embedded in them trying to tackle the disease - and why at the moment both are struggling.This episode of The Documentary comes to you from Assignment, investigations and journeys into the heart of global events.

According to the Guinness Book of World Records, TB is humanity's oldest contagious disease. It has become something of an afterthought in rich nations, but remains the world's most deadly infectious disease. In 2024 it killed more than 1.2 million people.South Africa has one of the highest TB burdens in the world, but it has also developed one of the most sophisticated scientific ecosystems for the study of the disease. Clinical trials conducted in the country have been crucial to the innovation of TB treatments, vaccines, diagnostics and prevention strategies.Much of the funding for this research comes from American institutions. But since early 2025, streams of that money have been withdrawn due to a series of decisions by the Trump administration. For Crossing Continents, Sandra Kanthal visits Cape Town and discovers the story of two intertwined landscapes: the people in local communities struggling with the burden of tuberculosis, and the scientific institutions embedded in them trying to tackle the disease - and why at the moment both are struggling.Presenter/Producer: Sandra Kanthal Producer in South Africa: Isa-Lee Jacobson Editor: Penny Murphy Sound Design: James Beard Production Coordinator: Katie Morrison

Intranasal vaccines are back in the spotlight as highly pathogenic avian influenza spreads among birds and spills over into mammals, including recent cases in dairy and poultry workers. In this episode of In Vivo, senior pharma and biotech reporter David Wild talks with Chad Costley, CEO of BlueWillow Biologics and Meagan Deming, an infectious disease researcher at the University of Maryland School of Medicine about a novel intranasal recombinant H5 flu vaccine that aims to stop infection at the gate by building mucosal immunity in the nose. They discuss recent Phase I data, pandemic‑flu preparedness, BARDA/NIH funding realities, and how BlueWillow's NanoVax platform could extend to other major respiratory threats, including TB.

Game 41: TB 7 at SJ 3 FINAL. TT: 00:15:00

We stray a little from our usual content with this episode and explore the topic of Tuberculosis. Rebecca did a deep dive into all things tuberculosis after reading John Greens book "Everything is Tuberculosis" and shares what she learned. While this episode isn't forensic focused it sure is interesting and like the title says, everything really is tuberculosis. From Sanitoriums, cowboy hats, and women's footwear we cover it all and how it relates back to the infamous sickness.(And if you have any fun TB facts feel free to share)Also, happy new year! We hope everyone had a fun and safe celebration and we're excited to see what 2026 brings! Thanks for joining us for yet another year of WTF!Interested in learning more about when WTF releases new episodes, contests, and more? Make sure to give us a follow on:Facebook: @whattheforensicsInstagram: @whattheforenicsTwitter: @WTForensicsPodYouTube: @whattheforensicsFor more details about the hosts, episode details, sources, and images related to each episode, check out our website at http://www.whattheforensics.caCreate your podcast today using the link: https://zencastr.com/?via=WTF #madeonzencastr#tuberculosis #johngreen #science #podcast Hosted on Acast. See acast.com/privacy for more information.

Check out part 1 w/ Dr. Dani here:    Dr. Dani LaMartina is a Doctor of Physical Therapy, an IFBB Olympian, a world-ranked powerlifter, a Coach, a Consultant, and a problem solver. Dr. Dani specializes in helping some of the world's top bodybuilders and powerlifters resolve stubborn pain without sacrificing hard training. She's the founder/lead at Paradigm Performance & Education, bringing a rare blend of doctoral-level clinical expertise and real "under-the-bar" experience to training, rehab, and long-term durability.   Dr. Dani is the most intelligent person I know when it comes to training, biomechanics, and improving health while enhancing hypertrophy. She's also one of the most compassionate, friendly, and amazing human beings I've ever met!   https://www.instagram.com/danilamartinadpt/ https://www.paradigm-performance.com/ dani@paradigm-performance.com       Use code "ScottM" at www.BiolongevityLabs.com to save on all Peptides including GLPs, BPC and TB, and much more! Get the best prices on quality, lab-tested peptides and help support the show.   Get the best health supplements, fish oil, and whey protein available at Legion Athletics. Use code "Scott_mys" to save! https://legionathletics.rfrl.co/p2g6m   This podcast is brought to you by LMNT Electrolytes! It's great for a hot summer day, a workout, or just working at your desk with cold water. Check it out and get your free sample pack along with any regular purchase when you use my custom link, www.drinklmnt.com/ScottMys. The LMNT Sample Pack includes one packet of their most popular flavors. This is the perfect offer for 1) anyone who is interested in trying all of our flavors or 2) anyone who wants to introduce a friend to LMNT. Go to www.drinklmnt.com/ScottMys to claim this awesome deal!   Interested in working with me 1-1? DM me on Instagram and I can answer any questions. If you like, we can even set up a FREE consult call to go over your goals, answer questions, and discuss what it could look like to work together!

An update on the story about an Apple developer who lost access to their Apple ID. Apple receives clearance to activate the Apple Watch hypertension detection feature in Australia. Italy fines Apple $115 million over App Tracking Transparency. And we say goodbye to one of the original MacBreak Weekly panelists. Apple developer's account restored after compromised gift card incident. Apple receives clearance to activate Apple Watch hypertension detection/notification feature in Australia. Apple agrees to third-party App Store alternatives in Brazil. Apple's iOS 26.3 will introduce proximity pairing to third-party devices in the EU. Free two-hour delivery from Apple Stores now available for a limited time. 1.5 TB of VRAM on Mac Studio - RDMA over Thunderbolt 5. Italy fines Apple $115 million over App Tracking Transparency. Apple announces more ads are coming to App Store search results Apple quietly discontinued flyover city tours in Apple Maps. Why Apple's foldable iPhone may be smaller than expected. Apple TV releasing Pluribus season finale early. Picks of the Week Alex's Pick: Homey Pro Andy's Pick: Ella Wishes You A Swinging Christmas & Patrick Stewart's 'A Christmas Carol' Jason's Pick: Some of his favorite books, TV shows, and podcasts from the past year. Hosts: Leo Laporte, Alex Lindsay, Andy Ihnatko, and Jason Snell Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: auraframes.com/ink

An update on the story about an Apple developer who lost access to their Apple ID. Apple receives clearance to activate the Apple Watch hypertension detection feature in Australia. Italy fines Apple $115 million over App Tracking Transparency. And we say goodbye to one of the original MacBreak Weekly panelists. Apple developer's account restored after compromised gift card incident. Apple receives clearance to activate Apple Watch hypertension detection/notification feature in Australia. Apple agrees to third-party App Store alternatives in Brazil. Apple's iOS 26.3 will introduce proximity pairing to third-party devices in the EU. Free two-hour delivery from Apple Stores now available for a limited time. 1.5 TB of VRAM on Mac Studio - RDMA over Thunderbolt 5. Italy fines Apple $115 million over App Tracking Transparency. Apple announces more ads are coming to App Store search results Apple quietly discontinued flyover city tours in Apple Maps. Why Apple's foldable iPhone may be smaller than expected. Apple TV releasing Pluribus season finale early. Picks of the Week Alex's Pick: Homey Pro Andy's Pick: Ella Wishes You A Swinging Christmas & Patrick Stewart's 'A Christmas Carol' Jason's Pick: Some of his favorite books, TV shows, and podcasts from the past year. Hosts: Leo Laporte, Alex Lindsay, Andy Ihnatko, and Jason Snell Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: auraframes.com/ink

An update on the story about an Apple developer who lost access to their Apple ID. Apple receives clearance to activate the Apple Watch hypertension detection feature in Australia. Italy fines Apple $115 million over App Tracking Transparency. And we say goodbye to one of the original MacBreak Weekly panelists. Apple developer's account restored after compromised gift card incident. Apple receives clearance to activate Apple Watch hypertension detection/notification feature in Australia. Apple agrees to third-party App Store alternatives in Brazil. Apple's iOS 26.3 will introduce proximity pairing to third-party devices in the EU. Free two-hour delivery from Apple Stores now available for a limited time. 1.5 TB of VRAM on Mac Studio - RDMA over Thunderbolt 5. Italy fines Apple $115 million over App Tracking Transparency. Apple announces more ads are coming to App Store search results Apple quietly discontinued flyover city tours in Apple Maps. Why Apple's foldable iPhone may be smaller than expected. Apple TV releasing Pluribus season finale early. Picks of the Week Alex's Pick: Homey Pro Andy's Pick: Ella Wishes You A Swinging Christmas & Patrick Stewart's 'A Christmas Carol' Jason's Pick: Some of his favorite books, TV shows, and podcasts from the past year. Hosts: Leo Laporte, Alex Lindsay, Andy Ihnatko, and Jason Snell Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: auraframes.com/ink

An update on the story about an Apple developer who lost access to their Apple ID. Apple receives clearance to activate the Apple Watch hypertension detection feature in Australia. Italy fines Apple $115 million over App Tracking Transparency. And we say goodbye to one of the original MacBreak Weekly panelists. Apple developer's account restored after compromised gift card incident. Apple receives clearance to activate Apple Watch hypertension detection/notification feature in Australia. Apple agrees to third-party App Store alternatives in Brazil. Apple's iOS 26.3 will introduce proximity pairing to third-party devices in the EU. Free two-hour delivery from Apple Stores now available for a limited time. 1.5 TB of VRAM on Mac Studio - RDMA over Thunderbolt 5. Italy fines Apple $115 million over App Tracking Transparency. Apple announces more ads are coming to App Store search results Apple quietly discontinued flyover city tours in Apple Maps. Why Apple's foldable iPhone may be smaller than expected. Apple TV releasing Pluribus season finale early. Picks of the Week Alex's Pick: Homey Pro Andy's Pick: Ella Wishes You A Swinging Christmas & Patrick Stewart's 'A Christmas Carol' Jason's Pick: Some of his favorite books, TV shows, and podcasts from the past year. Hosts: Leo Laporte, Alex Lindsay, Andy Ihnatko, and Jason Snell Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: auraframes.com/ink

An update on the story about an Apple developer who lost access to their Apple ID. Apple receives clearance to activate the Apple Watch hypertension detection feature in Australia. Italy fines Apple $115 million over App Tracking Transparency. And we say goodbye to one of the original MacBreak Weekly panelists. Apple developer's account restored after compromised gift card incident. Apple receives clearance to activate Apple Watch hypertension detection/notification feature in Australia. Apple agrees to third-party App Store alternatives in Brazil. Apple's iOS 26.3 will introduce proximity pairing to third-party devices in the EU. Free two-hour delivery from Apple Stores now available for a limited time. 1.5 TB of VRAM on Mac Studio - RDMA over Thunderbolt 5. Italy fines Apple $115 million over App Tracking Transparency. Apple announces more ads are coming to App Store search results Apple quietly discontinued flyover city tours in Apple Maps. Why Apple's foldable iPhone may be smaller than expected. Apple TV releasing Pluribus season finale early. Picks of the Week Alex's Pick: Homey Pro Andy's Pick: Ella Wishes You A Swinging Christmas & Patrick Stewart's 'A Christmas Carol' Jason's Pick: Some of his favorite books, TV shows, and podcasts from the past year. Hosts: Leo Laporte, Alex Lindsay, Andy Ihnatko, and Jason Snell Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: auraframes.com/ink

An update on the story about an Apple developer who lost access to their Apple ID. Apple receives clearance to activate the Apple Watch hypertension detection feature in Australia. Italy fines Apple $115 million over App Tracking Transparency. And we say goodbye to one of the original MacBreak Weekly panelists. Apple developer's account restored after compromised gift card incident. Apple receives clearance to activate Apple Watch hypertension detection/notification feature in Australia. Apple agrees to third-party App Store alternatives in Brazil. Apple's iOS 26.3 will introduce proximity pairing to third-party devices in the EU. Free two-hour delivery from Apple Stores now available for a limited time. 1.5 TB of VRAM on Mac Studio - RDMA over Thunderbolt 5. Italy fines Apple $115 million over App Tracking Transparency. Apple announces more ads are coming to App Store search results Apple quietly discontinued flyover city tours in Apple Maps. Why Apple's foldable iPhone may be smaller than expected. Apple TV releasing Pluribus season finale early. Picks of the Week Alex's Pick: Homey Pro Andy's Pick: Ella Wishes You A Swinging Christmas & Patrick Stewart's 'A Christmas Carol' Jason's Pick: Some of his favorite books, TV shows, and podcasts from the past year. Hosts: Leo Laporte, Alex Lindsay, Andy Ihnatko, and Jason Snell Download or subscribe to MacBreak Weekly at https://twit.tv/shows/macbreak-weekly. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit Sponsor: auraframes.com/ink

Summary In this truncated replay from the 2025 SF Derm Annual Conference, Dr. David Cotter discusses the implications of latent tuberculosis in dermatology, particularly in psoriasis treatment. He highlights the prevalence of latent TB, risk factors, and the importance of targeted screening. This session also addresses the mental health challenges faced by psoriasis patients and evaluates the safety of new treatments, emphasizing the need for careful monitoring and patient support. Takeaways - The prevalence of latent TB infection in the U.S. is 5%. - Healthcare workers have a higher risk of latent TB. - Patients on TNF inhibitors are significantly more likely to develop active TB. - Screening for latent TB should be targeted to high-risk patients. - Annual TB screening is not necessary for most psoriasis patients on IL-17 and IL-23 inhibitors. - The cost of screening for latent TB can be substantial. - Patients with psoriasis have higher rates of suicidal ideation and behavior. - Effective psoriasis treatment can improve mental health outcomes. - The event rate for suicide in clinical trials is very low. - Monitoring for mental health issues is crucial in psoriasis treatment. Chapters 00:00 - Understanding Latent Tuberculosis in Dermatology 08:40 - Mental Health and Psoriasis: A Critical Connection

How AI Is Targeting Malaria at Its SourceDrones, AI and a radically targeted approach to malaria prevention - this week Ania speaks with Mary Yeboah Ansawa from Ghana's Sora Technology about locating larvae-filled puddles before mosquitoes grow up to bite. From cutting pesticide use to saving field teams days of work, we dive into how this tech could reshape malaria control across Africa.India's TB Breakthrough—And a Privacy StormBack in MumbaiChavi Sajdev updates us on new TB diagnostics that swap messy sputum tests for simple oral swabs—faster, safer and far more accessible. Then: why India's plan to preload every new phone with a government cyber-security app sparked a nationwide backlash and pushback from major tech companies.Somewhere on Earth - voices from Ghana to India, innovation to controversy - all in one episode.The programme is presented by Ania Lichtarowicz.Production manager: Liz TuohyEditor: Ania Lichtarowicz

Bài của Chủ Tịch Dallin H. Oaks của Giáo Hội Các Thánh Hữu Ngày Sau của Chúa Giê Su Ky Tô Vào mùa Giáng Sinh này, tất cả Ky Tô Hữu trên khắp thế giới ăn mừng sự giáng sinh của Chúa Giê Su Ky Tô, vị “Hoàng Tử Bình An.” Tất cả chúng ta […] The post Podcast số 528 – Buổi Họp Đặc Biệt Giáng Sinh năm 2019 – Phúc Âm Bình An – Dallin H. Oaks appeared first on Thánh Hữu Việt Nam.

Eva mala iba 16 rokov, keď sa vrátila z koncentračného tábora. Doma našla iba otca, ktorý gestapu ušiel doslova zázrakom. Z koncentračného tábora, kde väzňov triedil doktor Mengele, sa však nikdy nevrátil ani jej starší brat, ani stará mama. Eva na krajinu, ktorá umožnila deportácie vlastných občanov, nezanevrela. Pre emigráciu sa rozhodla až po tom, keď jej manžela ŠtB nútila do spolupráce výmenou za víza. Jej dcére zase komunisti neumožnili študovať. V zahraničí sa neskôr stala významnou vedkyňou.

Download the Pikkit App (use code "bdge" to follow my picks) https://pikkit.onelink.me/zNwU/z60huf7lBecome a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricingRanking Every Week 16 Running Back as a Start or Sit: https://www.youtube.com/watch?v=dEFixnsDWaM0:00 - it's rude to skip intros0:22 - LAR vs SEA2:24 - PHI vs WAS348 - GB vs CHI6:48 - CLE vs BUF7:31 - CIN vs MIA9:49 - KC vs TEN11:32 - LAC vs DAL12:06 - MIN vs NYG15:07 - NYJ vs NO16:33 - TB vs CAR18:33 - ATL vs ARI20:46 - JAX vs DEN23:50 - LV vs HOU24:10 - PIT vs DET24:56 - BAL vs NE26:26 - IND vs SFsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAythis video is about (bdge,nick ercolano,fantasypros,fantasy flock,fantasy footballers,bdge fantasy football,2025 fantasy football,week 16,week 16 rankings,wide receiver rankings week 16,week 16 wide receiver rankings,fantasy football start sit week 16,week 16 start em sit em,fantasy football rankings week 16,start or sit,week 16 wr rankings,start em sit em,week 16 start sit,week 16 fantasy football)Support this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Do we sweat the same way vegetables do? What should I do if a billionaire sits down at my dinner table? How do I feel sane in today's world? Can you please tell my twelve year old son to go to sleep? How did we decide the geological time scales? When were chairs invented? How does John manage his fear of TB contamination? What is Salinger-ing? …Hank and John Green have answers!If you're in need of dubious advice, email us at hankandjohn@gmail.com.Join us for monthly livestreams at patreon.com/dearhankandjohn.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Become a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:25 - LAR vs SEA3:15 - PHI vs WAS4:36 - GB vs CHI6:24 - CLE vs BUF7:47 - CIN vs MIA8:10 - KC vs TEN9:19 - LAC vs DAL10:41 - MIN vs NYG11:50 - NYJ vs NO13:56 - TB vs CAR16:49 - ATL vs ARI18:02 - JAX vs DEN19:06 - LV vs HOU20:34 - PIT vs DET22:40 - BAL vs NE23:56 - IND vs SFsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAySupport this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Dr. Dani LaMartina is a Doctor of Physical Therapy, an IFBB Olympian, a world-ranked powerlifter, a Coach, a Consultant, and a problem solver. Dr. Dani specializes in helping some of the world's top bodybuilders and powerlifters resolve stubborn pain without sacrificing hard training. She's the founder/lead at Paradigm Performance & Education, bringing a rare blend of doctoral-level clinical expertise and real "under-the-bar" experience to training, rehab, and long-term durability.   Dr. Dani is the most intelligent person I know when it comes to training, biomechanics, and improving health while enhancing hypertrophy. She's also one of the most compassionate, friendly, and amazing human beings I've ever met!   https://www.instagram.com/danilamartinadpt/ https://www.paradigm-performance.com/ dani@paradigm-performance.com   Use code "ScottM" at www.BiolongevityLabs.com to save on all Peptides including GLPs, BPC and TB, and much more! Get the best prices on quality, lab-tested peptides and help support the show.   Get the best health supplements, fish oil, and whey protein available at Legion Athletics. Use code "Scott_mys" to save! https://legionathletics.rfrl.co/p2g6m   This podcast is brought to you by LMNT Electrolytes! It's great for a hot summer day, a workout, or just working at your desk with cold water. Check it out and get your free sample pack along with any regular purchase when you use my custom link, www.drinklmnt.com/ScottMys. The LMNT Sample Pack includes one packet of their most popular flavors. This is the perfect offer for 1) anyone who is interested in trying all of our flavors or 2) anyone who wants to introduce a friend to LMNT. Go to www.drinklmnt.com/ScottMys to claim this awesome deal!   Interested in working with me 1-1? DM me on Instagram and I can answer any questions. If you like, we can even set up a FREE consult call to go over your goals, answer questions, and discuss what it could look like to work together!

Join Ryan Wormeli and Andrew Erickson as they make predictions and highlight their favorite prop bets ahead of Week 16 of the NFL season! Timestamps: (May be off due to ads) Intro - 0:00:00 Predictions Recap - 0:01:57 MNF Recap - 0:03:05 Erickson Prediction 5: Chiefs lose to the Titans, Tony Pollard is a top-24 RB for the third straight week. Prop: Pollard over 51.5 rushing yards - 0:06:12 Worm Prediction 5: The Chiefs offense is actually okay without Patrick Mahomes…at least for this week. Prop: Travis Kelce Anytime TD - 0:10:27 Betting Pros Free Month Premium Offer Promo - 0:14:49 Erickson Prediction 4: T-Mac finishes top-20 in Week 16 vs TB. Prop: Tetairoa McMillan over 59.5 rec yards - 0:15:08 Worm Prediction 4: Cardinals-Falcons gives us two top-5 TEs. Prop: Kyle Pitts Over Receptions total - 0:20:29 Erickson Prediction 3: Omarion Hampton RB1 szn. Prop: Hampton over 47.5 rushing yards - 0:28:41 Worm Prediction 3: We finally get a Justin Jefferson Game again, finishes top-15 for the first time since Week 5. Prop: Jefferson Anytime TD - 0:32:46 Signed Bijan Robinson and Drake London Mini Helmet Giveaway Promo - 0:37:05Worm Prediction 2: Quinshon Judkins breaks out of his slump, finishes top-12 against Buffalo. Prop: Judkins Anytime TD - 0:37:35 Erickson Prediction 2: Ravens TEs bounce back vs the Patriots. Isaiah Likely finishes top-12 in Week 16. Prop: Lamar Jackson over 1.5 passing TDs - 0:41:06 Hard Rock Best Bets of the Week - 0:47:52 Hard Rock Bet FYP Promo - 0:54:12 What's your favorite Christmas Movie? - 0:55:30 Outro - 0:58:52 Helpful Links: Hard Rock Bet - All lines provided by Hard Rock Bet. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for Hard Rock Bet and make a $5 bet and you'll get $150 in bonus bets if you win. Head over to Hard Rock Bet, sign up and make your first deposit today. Payable in bonus bet(s). Not a cash offer. Offered by the Seminole Tribe of Florida in FL. Offered by Seminole Hard Rock Digital, LLC, in all other states. Must be 21+ and physically present in AZ, CO, FL, IL, IN, MI, NJ, OH, TN or VA to play. Terms and conditions apply. Concerned about gambling? In FL, call 1-833-PLAYWISE. In IN, if you or someone you know has a gambling problem and wants help, call 1-800-9-WITH-IT. GAMBLING PROBLEM? CALL 1-800-GAMBLER (AZ, CO, IL, MI, NJ, OH, TN, VA) My Playbook - Sync your league instantly to My Playbook to get custom advice on how to manage your team throughout the season. See your league’s top available players, power rankings, and more for free! Check the “Are They Playing” tool each week to get the latest game-day availability odds for all injured players. If you’re premium – you unlock all kinds of helpful waiver, trade, lineup and league analysis tools. You can even auto-start your team’s optimal lineup each week with Auto-Pilot. Sync your league and dominate every week of the season with My Playbook at fantasypros.com/myplaybook or on the FantasyPros App Follow us on Twitch - The team here at FantasyPros is taking questions all week, every week on Twitch. Follow us on Twitch at twitch.tv/fantasypros and never miss a stream! Discord – Join our FantasyPros Discord Community! Chat with other fans and get access to exclusive AMAs that wind up on our podcast feed. Come get your questions answered and BE ON THE SHOW at fantasypros.com/chat Leave a Review – If you enjoy our show and find our insight to be valuable, we’d love to hear from you! Your reviews fuel our passion and help us tailor content specifically for YOU. Head to Apple Podcasts, Spotify, or wherever else you get your podcasts and leave an honest review. Let’s make this show the ultimate destination for fantasy football enthusiasts like us. Thank you for watching and for showing your support – https://fantasypros.com/review/ BettingPros Podcast – For advice on the best picks and props across both the NFL and college football each and every week, check out the BettingPros Podcast at bettingpros.com/podcast, our BettingPros YouTube channel at youtube.com/bettingpros, or wherever you listen to podcastsSee omnystudio.com/listener for privacy information.

The recently passed Pennsylvania state budget includes more money for tuberculosis prevention efforts in the Commonwealth. Federal data show cases of TB steadily rising nationally after nearly three decades of decline. The University of Pittsburgh Medical Center is establishing a rural residency program in an effort to bolster the rural doctor workforce. Here’s how it works: Residents start at UPMC Williamsport before transferring to either UPMC Wellsboro or UPMC Cole in Coudersport. Both locations are in Pennsylvania’s northern tier known as the Pennsylvania Wilds region. In Cumberland County, an 80-year-old woman was found dead after a house fire early Sunday morning, according to the Cumberland County Coroner's Office. State officials discovered a month's worth of mail wasn't sent by a government-contracted mail house over the past month. The backlog of mail totals 3.4 million letters, including notices of SNAP eligibility and health benefit information, as well as driver’s license and vehicle registration renewal invitations from PennDOT. Pennsylvania lawmakers could end the year with the lowest number of new laws in at least a decade. That's due to split government, heightened partisanship, and the concentration of power in the hands of legislative leaders, according to reporting by our partners at Spotlight PA. Sunday marked the beginning of Hanukkah. The city of Lancaster and the Jewish Community Alliance of Lancaster hosted a menorah lighting in Penn Square. Did you know that if every sustaining circle member gives as little as $12 more a month, we'd close the gap caused by federal funding cuts? Increase your gift at https://witf.org/increase or become a new Sustaining Circle member at www.witf.org/givenow.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.

TB's Eagles beat reporter Andrew DiCecco gives his insights from covering the Eagles on a daily basis.In this episode, he goes inside the Eagles' elevation for Sunday's game against the Raiders and has some final thoughts on the matchup.

Become a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:21 - TB vs ATL3:06 - HOU vs ARI4:43 - CIN vs BAL6:05 - BUF vs NE7:26 - CLE vs CHI9:05 - LAC vs KC9:43 - LV vs PHI10:45 - NYJ vs JAX13:02 - WAS vs NYG14:31 - CAR vs NO15:24 - LAR vs DET16:22 - GB vs DEN18:09 - IND vs SEA19:35 - SF vs TEN20:30 - MIN vs DAL22:29 - PIT vs MIAsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAythis video is about (Support this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Download the Pikkit App (use code "bdge" to follow my picks) https://pikkit.onelink.me/zNwU/z60huf7lBecome a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:20 - TB vs ATL1:51 - HOU vs ARI2:37 - CIN vs BAL3:25 - BUF vs NE7:20 - CLE vs CHI9:24 - LAC vs KC11:41 - LV vs PHI13:29 - NYJ vs JAX14:52 - WAS vs NYG16:48 - CAR vs NO19:00 - LAR vs DET20:25 - GB vs DEN21:23 - IND vs SEA23:34 - SF vs TEN24:27 - MIN vs DAL25:37 - PIT vs MIAsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAythis video is about (Support this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

With THE MASTER OF CONTRADICTIONS: Thomas Mann and the Making of The Magic Mountain (Yale University Press), Morten Høi Jensen brings us a masterful biography of one of the great novels of the 20th century and shows how it and its author speak to our present moment. We talk about Morten's history with Mann's novel, his weeks of research in the sanatoria of Davos and his discovery of how much of The Magic Mountain's world is intact a century later, and how Mann's novel changed for him in the process of writing this book. We get into Mann's political transformation from a nationalist into an antifascist, how art & politics can make for a disastrous mix, Mann's rivalry with his novelist brother Heinrich, and what it was like to write about a novel about life in a TB clinic while in the middle of a pandemic. We also discuss the weird connection I draw between Mann and Thomas Pynchon, how Morten became a literary biographer via the biography of another novel, spiritualism before and after WWI, how he came around on the chapter of The Magic Mountain that bored him in his earlier readings, why Robert Musil resented Mann, whether it's okay to write margin notes and never look at them, and more. Follow Morten on Instagram and Bluesky • More info at our site • Support The Virtual Memories Show via Stripe, Patreon, or Paypal, and subscribe to our e-newsletter

Episode 208: Cough Basics (Pidjin English)Written by Ebenezer DadzieYou are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Episode 201: Cough – Revised Version (Host + 1 Resident; Resident speaks Nigerian Pidgin, Host speaks regular English)[Play intro music, start loud, then lower volume under speech, fade out later]HOST 1:[Introduction]Today we're tackling one of the most common complaints in clinic: the cough. Joining me is one of our amazing residents. Doctor, please introduce yourself.RESIDENT:Na Dr. Resident from Rio Bravo. I dey here to gist about cough wey dey disturb plenty patients for area.Segment 1 – Cough BasicsHOST 2:Let's start simple. When a coughing patient walks into the exam room, what is the first step?RESIDENT:First tin na history. You gats ask whether na dry cough or cough wey dey bring sputum, whether e just start or don tey. Whether person get exposure, dust, new medicine—history dey open many doors pass Google.HOST 1:Exactly. And as we know, acute coughs are usually viral, but chronic coughs lasting more than eight weeks can point to asthma, GERD, ACE inhibitor side effects, or more.Segment 2 – Valley FeverHOST 2:And since we're here in Kern County, we have to mention Valley Fever. We see thousands of cases every year, many of them presenting with cough.RESIDENT:True. Valley Fever fit look like pneumonia, bronchitis, or even TB. Patient go come with cough, tiredness, sometimes rash. If person dey work for outside or dey around dusty area, you suppose reason am.Segment 3 – Workup and TreatmentHOST 1:So let's talk evaluation. When you have a cough here in California's Central Valley, what is your approach?RESIDENT:Start from basic: chest X-ray, CBC, ask good history. If e no improve, add Valley Fever blood test. If cough get phlegm, you fit send sputum. If weight dey drop or sweats dey night, you reason TB or cancer. Treatment depend on severity. Mild one fit resolve, but if no be small, na antifungals—like fluconazole—and you go monitor liver enzymes well.Segment 4 – Humor BreakHOST 2:Alright—quick humor break. Got any memorable cough stories?RESIDENT:One man tell me say “doctor, my neighbor ghost na cause my cough.” We check-am finish, na allergy. Ghost no dey push fungus, sha![Both laugh]Segment 5 – TakeawaysHOST 1:Before we wrap up, give listeners top key points on cough.RESIDENT:One—ask better history. Cough dey tell story.Two—if person dey Bakersfield, reason Valley Fever, e fit sneak.Three—no dey give antibiotics anyhow. Virus and fungus no go respond like bacteria.Trivia TimeHOST 2:Trivia question: In adults who don't smoke and aren't on ACE inhibitors, what is the most common cause of chronic cough?A) AsthmaB) GERDC) Chronic bronchitisD) Postnasal drip (Upper airway cough syndrome)RESIDENT:I go choose D—postnasal drip. Na e dey cause that tickle wey no dey go.HOST 1:And that's correct—postnasal drip is the number one cause of chronic cough. Nicely done! You win bragging rights and a cough drop.HOST 2:Thank you for joining us today on Rio Bravo QWeek. To all our listeners—stay curious, keep learning, and if someone sounds like a barking seal in the waiting room, you know it might be more than a cold.HOST & RESIDENT (together):¡Hasta luego![Music fades in, rises, then fades out after 10 seconds]References:Irwin, R. S., & Baumann, M. H. (2018). Chronic cough due to upper airway cough syndrome (UACS): ACCP evidence-based clinical practice guidelines. Chest, 129(1_suppl), 63S–71S. https://doi.org/10.1378/chest.129.1_suppl.63S(Guideline on postnasal drip/upper airway cough syndrome as a leading cause of chronic cough)Dicpinigaitis, P. V. (2022). Evaluation and management of chronic cough. New England Journal of Medicine, 386(16), 1532–1541. https://doi.org/10.1056/NEJMra2115321(Comprehensive review on causes, diagnostic strategies, and treatment of chronic cough)Centers for Disease Control and Prevention. (2023). Coccidioidomycosis (Valley fever) statistics. U.S. Department of Health and Human Services. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.html(Official CDC data and epidemiology of Valley Fever in the U.S., including high incidence in Kern County)California Department of Public Health. (2022). Coccidioidomycosis in California Provisional Monthly Report. https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/Coccidioidomycosis.aspx(State-level surveillance data showing high incidence rates in Bakersfield and Kern County)Prasad, K. T., & LoSavio, P. S. (2023). Approach to the adult with chronic cough. In UpToDate (L. M. Leung, Ed.). Retrieved June 20, 2025, from https://www.uptodate.com(Evidence-based resource for differential diagnosis and workup of cough in primary care)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Whether you’re rebuilding or win-now, dominate future seasons with our 2025 dynasty rookie draft do-over! What makes New York Giants QB Jaxson Dart the clear 1.01 selection? Is Las Vegas Raiders RB Ashton Jeanty going in the top three still justified? Plus, how far has Tennessee Titans QB Cam Ward fallen? Seth, Eric & Steve reveal the top-32 players in their updated superflex rankings for the most recent rookie class on a new podcast! ⏰ Time Stamps: 00:00:00 Introduction 00:05:36 IBT Football Family Promo 00:06:47 Front & Center: 2025 Dynasty Rookie Draft Do-Over 00:08:25 Tier 1: Jaxson Dart (QB – NYG), Tetairoa McMillan (WR – CAR) & Ashton Jeanty (RB – LV) 00:15:13 Tier 2: TreVeyon Henderson (RB – NE), Tyler Warren (TE – IND), Emeka Egbuka (WR – TB) & Cam Ward (QB – TEN) 00:23:52 Tier 3: Omarion Hampton (RB – LAC), Quinshon Judkins (RB – CLE) & Cam Skattebo (RB – NYG) 00:29:08 Tier 4: Jayden Higgins (WR – HOU) & RJ Harvey (RB – DEN) 00:31:27 Tier 5: Oronde Gadsden II (TE – LAC), Travis Hunter (WR/CB – JAX), Woody Marks (RB – HOU), Matthew Golden (WR – GB), Colston Loveland (TE – CHI) & Luther Burden III (TE – CHI) 00:38:24 Tier 6: Harold Fannin Jr. (TE – CLE), Bhayshul Tuten (RB – JAX), Kyle Monangai (RB – CHI), Tre Harris (WR – LAC), Elic Ayomanor (WR – TEN) & Kaleb Johnson (RB – PIT) 00:45:20 Honorable Mentions: Mason Taylor (TE – NYJ), Tory Horton (WR – SEA), Shedeur Sanders (QB – CLE), Tyler Shough (WR – NO), Chimere Dike (WR – TEN), Devin Neal (RB – NO), Pat Bryant (WR – DEN) & Jacory Croskey-Merritt (RB – WAS) 00:50:02 Between Bets: NFL Week 14 Picks & Predictions 00:52:30 Chicago Bears +6.5 (-108 via DraftKings) vs. Green Bay Packers 00:55:43 Houston Texans +3.5 (-118 via DraftKings) vs. Kansas City Chiefs 00:57:00 Arizona Cardinals +8.5 (-115 via FanDuel) vs. Los Angeles Rams 00:57:21 Dallas Cowboys @ Detroit Lions (+142 via DraftKings) 00:58:33 Washington Commanders ML (+118 via Hard Rock Bet) vs. Minnesota Vikings 01:02:17 Cleveland Browns OVER 19.5 Points (-111 via FanDuel) vs. Tennessee Titans 01:03:58 Tennessee Titans vs. Cleveland Browns OVER 33.5 (-110 via DraftKings) 01:05:25 Miami Dolphins vs. New York Jets OVER 40.5 (-110 via DraftKings) 01:06:54 New Orleans Saints vs. Tampa Bay Buccaneers OVER 42.5 (-102 via DraftKings) 01:08:11 George Pickens Over 77.5 Receiving Yards (-114 via FanDuel) 01:09:09 Devaughn Vele Over Receiving Yards or Receptions 01:10:03 Tyler Shough Over 218.5 Passing Yards (-114 via FanDuel) 01:10:41 Rashee Rice Over 62.5 Receiving Yards (-117 via BetRivers) 01:12:39 Zonovan Knight Over Receiving Yards 01:13:41 Touchdown Calls of the Week & Leaderboard Update 01:15:49 Jonathan Taylor Anytime TD (-250 via bet365) 01:16:28 Rashee Rice Anytime TD (+125 via BetMGM) 01:17:09 De'Von Achane Anytime TD (-140 via DraftKings) 01:17:40 Chris Rodriguez Jr. Anytime TD (NL) 01:18:21 RJ Harvey Anytime TD (NL) 01:19:38 Jameson Williams Anytime TD (+110 via DraftKings) 01:20:56 Listener Questions No. 1 01:23:59 Plugs + Outro

Sometimes, winning in your fantasy football playoffs is about owning a piece of the right offenses at the right time. That'll be one of the driving forces of our tape review the rest of the season: sharpening our focus on offenses (like the Patriots on Monday night!) that appear to be wagons, or at least wagon-adjacent. Do the Jaguars belong in that category? How about the Cardinals' potential waiver guys? We'll discuss what we saw on film for the rest of the Week 13 games, and then spin it forward and talk about the adds you need to make in advance of Week 14! Guest: John Daigle of Establish The Run.   NOTES: Sponsor - www.WildGrain.com/harris for $30 off your subscription of artisanal bread, pasta and pastries Sponsor - pick6.draftkings.com/ to make one $5 pick set and get $50 in bonus picks when you use the code HARRIS Sponsor - www.leesa.com code HARRIS for 30% off and an extra $50 discount on a great mattress Follow John Daigle - https://bsky.app/profile/johndaigle.bsky.social Follow our show on Bluesky - https://bsky.app/profile/harrisfootball.com Follow on Twitter - @HarrisFootball Become a Person of the Book - https://www.amazon.com/Christopher-Harris/e/B007V3P4KK Watch the YouTube channel - www.youtube.com/harrisfootball Harris Football Yacht Club Dictionary - https://harrisfootball.github.io/dictionary.html Join the Harris Football Subreddit - www.reddit.com/r/HarrisFootball Subscribe To the Yacht Club Premium Podcast - https://harrisfootball.supportingcast.fm/   Week 13 Game Film Discussed Today: NYG/NE ATL/NYJ MIN/SEA NO/MIA JAC/TEN   John's Week 14 Waiver Adds: 5. Isaac TesLaa - 1% 4. Bam Knight - 26% 3. Brenton Strange - 33% 2. Chris Rodriguez - 24% 1. A.D. Mitchell - 3%   Chris's Week 14 Waiver Adds: 5. Isaac TesLaa - 1% 4. A.D. Mitchell - 3% 3. Devin Singletary - 22% 2. Bam Knight - 26% 1. Chris Rodriguez - 24% (h.m. - Brenton Strange - 33%; Kayshon Boutte - 33%; Greg Dortch - 10%; Devaughn Vele - 1%; Pat Bryant - 2%) (QB - Tyrod Taylor vs. MIA; Tua Tagovailoa @NYJ; Tyler Shough @TB) (DEF - MIN vs. WAS; WAS @ MIN; TB vs. NO; MIA @ NYJ)

Today, synthetic bacteriophages, a breakthrough vaccine for TB, and how unpicking the pathways used to make antibiotics are helping scientists to combat rising rates of antimicrobial resistance around the world... Like this podcast? Please help us by supporting the Naked Scientists

What if the future of fat loss and rapid recovery isn't a supplement, a workout program, or a diet plan, but a molecule your body already knows how to use? In this in-studio episode of the Metabolic Freedom Podcast, Ben Azadi sits down with Dr. Robert Bello, chiropractor and founder of Bio Thrive Peptides, for an eye-opening conversation about peptides like BPC-157 and TB-4 Frag. They explore how these compounds accelerate healing, support fat loss, restore joint function, boost hormone signaling, and reduce chronic inflammation safely and naturally. Dr. Bello breaks down the science behind peptide therapy, dosing strategies, sourcing standards, safety considerations, and red flags to avoid when purchasing peptides. Ben also shares his personal experience using The Wolverine Stack and the noticeable improvements in strength, recovery, and energy. If you're curious about peptides, longevity medicine, or solutions for chronic pain and inflammation, this episode is a must-listen.

Segment 1 – News and Notes1.We had our first significant trade of the season as the Orioles traded Grayson Rodriguez to the Angels for Taylor Ward.a.Both teams are starved for pitching, and while G-Rod has never been healthy, he has good stuff with four years of team control. Taylor Ward becomes a free agent after this season.b.Unless the Orioles haven't told us that G-Rod's arm will fall off at some point next season, it's hard not to like this for the Angels. I will say, the Angels did not do a physical. I'm thinking that was part of the deal – you're buying low, so no give-backzy. 2.Raisel Iglesias signed back with the Braves. He had stretch where he was awful and lost his job. Is he the closer going into camp? Is he somebody you're comfortable drafting as a closer?3.Non-tendered players – Surprised, any worries they will sign somewhere?a.Adolis Garica (OF, Tex)i.Who gets his playing time?b.Nathaniel Lowe (1B, Bos)c.Christopher Morel (DH, TB)d.Alek Manoah (Atl, RHP)4.Kazuma Okamoto was posted. What do we know about him?Segment 2 – Fantasy Questions of the NL East – Marlins, Mets, Phillies, and NatsMiami Marlins1.Jakob Marsee – Let's hear it.a.AB, HR, SB, and BA – 12 HR, 35 SB, .2702.I know you've been a big fan of Connor Norby in the past. In a bit over a half-season, he went 8-8, making him a 15-15 player with a .250ish batting average. That's not an awful player, but he's been drafted as one. His ADP is 387, and he's the 30th third baseman off the board.a.What are your thoughts on Noby this season? Are you interested?3.Kyle Stowers had his breakout last season, posting a .288 batting average with 25 home runs in only 117 games. He's going as the 28th outfielder off the board.a.Would you feel good about him being your #2 outfielder?4.Sandy Alcantara was terrible last season, and now he's the 66th pitcher off the board (50th starter). I think I recall you saying you wanted him to pitch poorly last year, so he would drop in 2026. Has he dropped enough for you to be interested?5.When Ryan Weather has played, he's been ok. Unfortunately, he seems always to be hurt. He's the 120th pitcher off the board (call it 85 to 90th starter) – your 6th starter. Is that someone who interests you at the moment, or is it a pass?6.Give me a sleeper in the organization (minor or majors)New York Mets1.The Mets appear to be moving on from Pete Alonso so they can move Vientos to first and Baty to third. Do you like this move or do you believe the Mets will keep Alonso?a.Baty's ADP is 259 and Vientos is 256. Who would you rather have?2.Francisco Alvarez started to show signs of being an impact player, slugging 11 home runs in 76 games. He'll just be 24 next season. Over/Under 20 home runs?3.Will Jeff McNeil be the full-time second baseman for the Mets in 2026? He's on the last year of his contract?4.Kodai Senga posted decent numbers in 2025, posting a 3.02 ERA with 109 strikeouts and 55 walks. However, he spent time in the minor leagues and continues to struggle throwing strikes?a.Stat line for 2026: wins, ERA, and K'sb.There's been rumors that the Mets will trade him this winter? What say you?5.Who will be the Mets closer in 2026?6.Give me a sleeper in the organization (minor or majors)Philadelphia Phillies1.The Phillies could lose several players to free agency, including Kyle Schwarber and JT Realmuto. Do they resign these guys or try to get younger?a.I guess the problem is, are there minor league players that can step in or do they need to dip into free agency?2.Related to #1, the Phillies team still has Harper, Turner, and Cristopher Sanchez, but overall, the team doesn't look great. Dumbroski always finds a way, but is this a playoff contender for 2026?3.Andrew Painter – 2026 stats – IP, ERA, K's4.Zach Wheeler is expected to be back by the end of May. Before the injury, he was one of the best pitchers in baseball, but he had TOS surgery, which doesn't have a great track record for pitchers. He's the 52nd pitcher off the board, or the 39th starting pitcher off the board. Do you feel comfortable with Wheeler being a stronger #3 starter on your team? He was a top 5 pitcher selected in 2025.5.Give me a sleeper in the organization (minor or majors)

In this episode, Liz and Becca share how to prepare your body before surgery and accelerate recovery after — without guessing or relying on outdated medical advice. They break down the exact nutrition, peptide, and recovery strategies that reduce inflammation, speed up healing, and help you feel like yourself again. Whether it's a C-section, tummy tuck, or hysterectomy, this episode covers what to eat, what to avoid, and how to use powerful tools like BPC-157 and TB-500 safely for faster repair and less scarring. ***CONNECT

Become a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:26 - BUF vs HOU3:02 - KC vs IND4:47 - MIN vs GB6:27 - NE vs CIN10:19 - NYG vs DET11:32 - NYJ vs BAL12:08 - PIT vs CHI13:38 - SEA vs TEN14:52 - LV vs CLE15:48 - JAX vs ARI18:04 - ATL vs NO21:10 - PHI vs DAL24:12 - TB vs LAR25:48 - CAR vs SFsubscribe to Your Idiot Leaguemates channel: https://www.youtube.com/@YourIdiotLeaguematessubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAySupport this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Download the Pikkit App (use code "bdge" to follow my picks) https://pikkit.onelink.me/zNwU/z60huf7lBecome a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:20 - BUF vs HOU2:48 - KC vs IND4:02 - MIN vs GB6:14 - NE vs CIN9:56 - NYG vs DET11:15 - NYJ vs BAL12:26 - PIT vs CHI13:53 - SEA vs TEN15:23 - LV vs CLE16:41 - JAX vs ARI18:42 - ATL vs NO19:08 - PHI vs DAL19:46 - TB vs LAR22:02 - CAR vs SFsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAythis video is about (Support this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Join Joe Pisapia, Chris Welsh, and Scott Bogman LIVE on Twitch every Monday afternoon at 2:00 PM ET at twitch.tv/fantasypros. The guys discuss everything happening in the football world, both in fantasy and in reality, while having some fun along the way! Put your bad day behind you with a new episode of "Out of Bounds," where Joe Pisapia, Chris Welsh and Scott Bogman share their top fantasy football Week 11 takeaways!Producer's Note: Ja'Marr Chase was suspended for 1 game after this was recorded. Timestamps: (May be off due to ads)Intro - 0:00:00Watch us on Twitch at twitch.tv/fantasypros - 0:00:10Fantasy Football Loser Belt Giveaway - 0:00:26Weekly Recap - 0:00:54Questions and Asses - 0:04:34Is Ja'Marr Chase getting suspended? - 0:04:44Bryce Young is a QB1 rest of season, Fact or Fiction? - 0:06:55What do you think about Chris Rodriguez rest of season? - 0:09:05What are your thoughts on where the Atlanta Falcons Offense is from a fantasy perspective? - 0:12:15Is Christian Watson as a feasible replacement for Drake London rest of season? - 0:13:11Who would you rather start this week Shedeur Sanders or Tyrod Taylor? - 0:17:48Has Jacoby Brissett played himself into a starting position next year? - 0:19:55Pick one team each from the AFC and NFC that will NOT make the playoffs. - 0:22:00Joe's Takeaway of the week: Bryce Young should ONLY play the Falcons from here on out. - 0:26:05Welsh's Takeaway of the week: This seems to be the most beatable Chiefs team in god knows how long. - 0:26:15Bogman's Takeaway of the week: The Vikings' weapons are downgraded while McCarthy figures it out. - 0:30:36Bogman's Moment of the week: Ja’Marr Chase should be suspended. - 0:32:55Welsh's Moment of the week: How about Michael Wilson 15-185 yards. - 0:33:32Joe's Moment of the week: Darnell Washington catch and run - 0:34:43Fact or Fiction - 0:35:40311 Contest Recap - 0:40:09Joe's 311 Picks: Jared Goff v NYG, Derrick Henry v. NYJ, Amon-Ra St. Brown v NYG - 0:40:24Welsh's 311 Picks: Drake Maye vs CIN, Saquon Barkley vs DAL, Tetairoa McMillan vs SF - 0:40:37Bogman's 311 Picks: Matthew Stafford vs TB, Jahmyr Gibbs vs NYG, JSN @ TEN - 0:41:37Fact or Fiction: Justin Herbert and Quinton Johnston are cooked rest of season - 0:43:35Twitch Promo - 0:45:19Outro - 0:45:34 Helpful Links: Hard Rock Bet - All lines provided by Hard Rock Bet. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for Hard Rock Bet and make a $5 bet and you'll get $150 in bonus bets if you win. Head over to Hard Rock Bet, sign up and make your first deposit today. Payable in bonus bet(s). Not a cash offer. Offered by the Seminole Tribe of Florida in FL. Offered by Seminole Hard Rock Digital, LLC, in all other states. Must be 21+ and physically present in AZ, CO, FL, IL, IN, NJ, OH, TN or VA to play. Terms and conditions apply. Concerned about gambling? In FL, call 1-888-ADMIT-IT. In IN, if you or someone you know has a gambling problem and wants help, call 1-800-9-WITH-IT. GAMBLING PROBLEM? CALL 1-800-GAMBLER (AZ, CO, IL, NJ, OH, TN, VA). My Playbook - Sync your league instantly to My Playbook to get custom advice on how to manage your team throughout the season. See your league’s top available players, power rankings, and more for free! Check the “Are They Playing” tool each week to get the latest game-day availability odds for all injured players. If you’re premium – you unlock all kinds of helpful waiver, trade, lineup and league analysis tools. You can even auto-start your team’s optimal lineup each week with Auto-Pilot. Sync your league and dominate every week of the season with My Playbook at fantasypros.com/myplaybook or on the FantasyPros App Follow us on Twitch - The team here at FantasyPros is taking questions all week, every week on Twitch. Follow us on Twitch at twitch.tv/fantasypros and never miss a stream! Discord – Join our FantasyPros Discord Community! Chat with other fans and get access to exclusive AMAs that wind up on our podcast feed. Come get your questions answered and BE ON THE SHOW at fantasypros.com/chat Leave a Review – If you enjoy our show and find our insight to be valuable, we’d love to hear from you! Your reviews fuel our passion and help us tailor content specifically for YOU. Head to Apple Podcasts, Spotify, or wherever else you get your podcasts and leave an honest review. Let’s make this show the ultimate destination for fantasy football enthusiasts like us. Thank you for watching and for showing your support – https://fantasypros.com/review/ BettingPros Podcast – For advice on the best picks and props across both the NFL and college football each and every week, check out the BettingPros Podcast at bettingpros.com/podcast, our BettingPros YouTube channel at youtube.com/bettingpros, or wherever you listen to podcasts.See omnystudio.com/listener for privacy information.

Become a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:37 - NE vs NYJ2:14 - WAS vs MIA3:10 - CAR vs ATL4:35 - CHI vs MIN7:17 - CIN vs PIT9:07 - GB vs NYG11:42 - HOU vs TEN13:24 - LAC vs JAX15:48 - TB vs BUF17:53 - SEA vs LAR19:16 - SF vs ARI21:34 - BAL vs CLE23:14 - KC vs DEN24:12 - DET vs PHI25:55 - LV vs DALsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAythis video is about (Support this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Download the Pikkit App (use code "bdge" to follow my picks) https://pikkit.onelink.me/zNwU/z60huf7lBecome a Big Dog Member here: https://bdge.co/memberships/fantasy_football/pricing0:00 - it's rude to skip intros0:19 - NE vs NYJ2:56 - WAS vs MIA3:56 - CAR vs ATL5:02 - CHI vs MIN6:43 - CIN vs PIT8:14 - GB vs NYG8:53 - HOU vs TEN10:19 - LAC vs JAX11:32 - TB vs BUF12:42 - SEA vs LAR15:00 - SF vs ARI16:39 - BAL vs CLE18:11 - KC vs DEN21:27 - DET vs PHI23:03 - LV vs DALsubscribe to the bdge dynasty channel: https://ytube.io/3pZklisten to the bdge dynasty podcast: https://bityl.co/NzJ1bdge nfl trivia youtube channel: https://ytube.io/3jmJjoin the BDGE discord: https://discord.gg/77BxrqCF6Fsubscribe to the BDGE podcast | https://linktr.ee/bdgefollow me on the socials | https://linktr.ee/nickercolanoContact▪️ business inquiries | business@bdge.co▪️ customer support/help | help@bdge.co▪️ fantasy questions can go in our discord | https://discord.gg/AvpY3QJTAythis video is about (Support this podcast at — https://redcircle.com/bdge-fantasy-football/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Join Joe Pisapia, Chris Welsh, and Scott Bogman LIVE on Twitch every Monday afternoon at 2:00 PM ET at twitch.tv/fantasypros. The guys discuss everything happening in the football world, both in fantasy and in reality, while having some fun along the way! Put your bad day behind you with a new episode of "Out of Bounds," where Joe Pisapia, Chris Welsh and Scott Bogman share their top fantasy football Week 10 takeaways! Timestamps: (May be off due to ads) Intro - 0:00:00ESPN Fantasy Football Championship Ring Giveaway Promo - 0:00:14Questions and Asses - 0:00:41Brian Daboll out as NYG HC. - 0:02:05Audience Question: What are we to do with Bucky Irving? - 0:07:39Joe Burrow Returns - 0:10:25Bills and Bears are both 6-3, which team is more of a fraud? - 0:13:33Could Jonathan Taylor be MVP this year? - 0:15:32Joe's takeaway of the week: The Patriots are going to win a playoff game this season. - 0:20:41Welsh's Takeaway of the Week: Let’s just shoot TNF into the Sun. - 0:24:43Bogman's takeaway of the week: The Jets are going to ride Breece Hall until the wheels fall off. - 0:27:37Bogman's moment of the week: The Patriots fan lady reacting to Henderson’s big TD run. - 0:28:33Joe's moment of the week: Davis Mills Dive. - 0:29:33Welsh's moment of the week: Dalton Schultz's 20-yard catch to complete the ladder from BP. - 0:30:10Fact or Fiction - 0:32:56311 Contest Recap - 0:42:14Joe's 311 Picks: Baker Mayfield @ BUF, Bijan Robinson v CAR, Emeka Egbuka @ BUF - 0:42:39Welsh's 311 Picks: Joe Flacco vs PIT, Rico Dowdle vs ATL, Jamarr Chase vs PIT - 0:43:02Bogman's 311 Picks: Josh Allen vs TB, DeVon Achane vs WAS, Jamarr Chase @ PIT - 0:45:22Outro - 0:46:43 Helpful Links: Hard Rock Bet - All lines provided by Hard Rock Bet. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for Hard Rock Bet and make a $5 bet and you'll get $150 in bonus bets if you win. Head over to Hard Rock Bet, sign up and make your first deposit today. Payable in bonus bet(s). Not a cash offer. Offered by the Seminole Tribe of Florida in FL. Offered by Seminole Hard Rock Digital, LLC, in all other states. Must be 21+ and physically present in AZ, CO, FL, IL, IN, NJ, OH, TN or VA to play. Terms and conditions apply. Concerned about gambling? In FL, call 1-888-ADMIT-IT. In IN, if you or someone you know has a gambling problem and wants help, call 1-800-9-WITH-IT. GAMBLING PROBLEM? CALL 1-800-GAMBLER (AZ, CO, IL, NJ, OH, TN, VA). My Playbook - Sync your league instantly to My Playbook to get custom advice on how to manage your team throughout the season. See your league’s top available players, power rankings, and more for free! Check the “Are They Playing” tool each week to get the latest game-day availability odds for all injured players. If you’re premium – you unlock all kinds of helpful waiver, trade, lineup and league analysis tools. You can even auto-start your team’s optimal lineup each week with Auto-Pilot. Sync your league and dominate every week of the season with My Playbook at fantasypros.com/myplaybook or on the FantasyPros App Follow us on Twitch - The team here at FantasyPros is taking questions all week, every week on Twitch. Follow us on Twitch at twitch.tv/fantasypros and never miss a stream! Discord – Join our FantasyPros Discord Community! Chat with other fans and get access to exclusive AMAs that wind up on our podcast feed. Come get your questions answered and BE ON THE SHOW at fantasypros.com/chat Leave a Review – If you enjoy our show and find our insight to be valuable, we’d love to hear from you! Your reviews fuel our passion and help us tailor content specifically for YOU. Head to Apple Podcasts, Spotify, or wherever else you get your podcasts and leave an honest review. Let’s make this show the ultimate destination for fantasy football enthusiasts like us. Thank you for watching and for showing your support – https://fantasypros.com/review/ BettingPros Podcast – For advice on the best picks and props across both the NFL and college football each and every week, check out the BettingPros Podcast at bettingpros.com/podcast, our BettingPros YouTube channel at youtube.com/bettingpros, or wherever you listen to podcasts.See omnystudio.com/listener for privacy information.